DexCom (NASDAQ:DXCM) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of DexCom (NASDAQ:DXCM) from a buy rating to a hold rating in a report issued on Saturday.

A number of other brokerages have also recently commented on DXCM. Wells Fargo & Company boosted their price target on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Piper Sandler restated an “overweight” rating and set a $90.00 price target on shares of DexCom in a report on Monday, August 26th. Oppenheimer dropped their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. UBS Group reduced their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Finally, BTIG Research cut their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $104.59.

DexCom Stock Down 0.9 %

NASDAQ:DXCM opened at $69.70 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm’s 50-day moving average price is $69.77 and its 200-day moving average price is $94.92. The company has a market capitalization of $27.22 billion, a PE ratio of 41.74, a P/E/G ratio of 2.16 and a beta of 1.17. DexCom has a 1-year low of $62.34 and a 1-year high of $142.00.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.30% of the company’s stock.

Institutional Trading of DexCom

Several hedge funds have recently modified their holdings of DXCM. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in DexCom during the second quarter valued at $25,000. Sachetta LLC grew its position in DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after acquiring an additional 171 shares in the last quarter. Crewe Advisors LLC bought a new stake in DexCom during the first quarter worth approximately $29,000. Riverview Trust Co raised its position in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the period. Finally, DT Investment Partners LLC lifted its stake in shares of DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 315 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.